- Home
- DMAC vs CRMT Comparison
DMAC vs CRMT Comparison
Compare DMAC & CRMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- CRMT
- Stock Information
- Founded
- DMAC 2000
- CRMT 1981
- Country
- DMAC United States
- CRMT United States
- Employees
- DMAC N/A
- CRMT N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- CRMT Other Specialty Stores
- Sector
- DMAC Health Care
- CRMT Consumer Discretionary
- Exchange
- DMAC Nasdaq
- CRMT Nasdaq
- Market Cap
- DMAC 310.1M
- CRMT 284.5M
- IPO Year
- DMAC N/A
- CRMT N/A
- Fundamental
- Price
- DMAC $6.87
- CRMT $32.20
- Analyst Decision
- DMAC Strong Buy
- CRMT Buy
- Analyst Count
- DMAC 3
- CRMT 1
- Target Price
- DMAC $12.33
- CRMT $45.00
- AVG Volume (30 Days)
- DMAC 448.5K
- CRMT 191.0K
- Earning Date
- DMAC 11-12-2025
- CRMT 09-04-2025
- Dividend Yield
- DMAC N/A
- CRMT N/A
- EPS Growth
- DMAC N/A
- CRMT N/A
- EPS
- DMAC N/A
- CRMT 1.61
- Revenue
- DMAC N/A
- CRMT $1,378,681,000.00
- Revenue This Year
- DMAC N/A
- CRMT $6.23
- Revenue Next Year
- DMAC N/A
- CRMT $5.10
- P/E Ratio
- DMAC N/A
- CRMT $20.03
- Revenue Growth
- DMAC N/A
- CRMT 0.64
- 52 Week Low
- DMAC $3.19
- CRMT $32.10
- 52 Week High
- DMAC $7.49
- CRMT $62.72
- Technical
- Relative Strength Index (RSI)
- DMAC 63.84
- CRMT 25.05
- Support Level
- DMAC $6.83
- CRMT $33.50
- Resistance Level
- DMAC $7.41
- CRMT $37.74
- Average True Range (ATR)
- DMAC 0.43
- CRMT 1.91
- MACD
- DMAC 0.03
- CRMT -0.62
- Stochastic Oscillator
- DMAC 73.62
- CRMT 1.05
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About CRMT America's Car-Mart Inc
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.